Related Experiment Video
Updated: May 17, 2026
11:12
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
HTERT MNS16A polymorphism in breast cancer: a case-control study
Flora Zagouri1, Theodoros N Sergentanis, Maria Gazouli
1Department of Clinical Therapeutics, Alexandra Hospital, University of Athens, Athens, Greece.
Molecular Biology Reports
|October 16, 2012
Summary
The HTERT MNS16A polymorphism is not associated with breast cancer risk or survival in Caucasian Greek women. Further research is needed to understand this genetic marker’s role in breast cancer.
Area of Science:
- Genetics
- Oncology
- Epidemiology
Background:
- Breast cancer is a significant global health concern.
- Genetic factors play a role in breast cancer development.
- The HTERT MNS16A polymorphism is a novel genetic marker under investigation.
Purpose of the Study:
- To evaluate the HTERT MNS16A polymorphism as a risk factor for breast cancer.
- To assess the HTERT MNS16A polymorphism as a prognostic marker for breast cancer survival.
- To investigate these roles in a Caucasian Greek population.
Main Methods:
- Case-control study design.
- Recruitment of 113 ductal breast cancer cases and 124 healthy controls.
- Genotyping of HTERT MNS16A polymorphism and multivariate logistic regression analysis.
Main Results:
- No significant association found between HTERT MNS16A polymorphism and breast cancer risk.
- No significant association observed for premenopausal or postmenopausal women.
- HTERT MNS16A polymorphism did not impact disease-free or overall survival.
Conclusions:
- HTERT MNS16A polymorphism does not appear to be a risk factor for breast cancer in this population.
- The polymorphism is not a prognostic marker for breast cancer survival.
- Larger, international studies are required to further examine this genetic polymorphism.
Related Concept Videos
01:12Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...
01:20Mismatch Repair
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...